Designing short lipidated peptides (SLiPs) to target intracellular drivers of disease

• Scaffold proteins interact with ion channels to regulate neuronal activity
• Short lipidated peptides (SLiPs) can be engineered to disrupt pathological complexes between scaffold proteins and ion channels
• MM-3001 is a fast-onset, long-acting, investigational SLiP for the treatment of chronic pain

Speakers:

John Strumbos

Chief Executive Officer

Mimetic Medicines